Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Psybio Therapeutics Corp (OP: PSYBF )

0.0079 +0.0009 (+12.86%)
Streaming Delayed Price Updated: 9:30 AM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,000
Open 0.0079
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0070
Today's Range 0.0079 - 0.0079
52wk Range 0.0030 - 0.0267
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MA, FL And OH Psychedelics Scientists And Educators' Latest Research And Views
Along with a growing scientific corpus supporting the therapeutic potential of psychedelics, several states and most noticeably Massachusetts are seeing the decriminalization of natural substances... 
Via Benzinga
EXCLUSIVE: Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'
Experts gathered at the Benzinga Psychedelics Capital Conference in Miami Beach on Thursday where they talked about revolutionizing psychedelic therapy as a promising new approach for treating mental... 
Via Benzinga

Performance

YTD
+54.90%
+54.90%
1 Month
+5.33%
+5.33%
3 Month
+33.90%
+33.90%
6 Month
+97.50%
+97.50%
1 Year
-64.09%
-64.09%

More News

Read More
Psyched: Psychedelic Therapy In The Workplace, UCL's Brain Imaging Study, COMPASS Trials And More
Via Benzinga
Psychedelics & Environmental Protection: Company Seeks Patents To Synthetically Produce Toad Venom
Via Benzinga
Psychedelics Production Methods Expect Further IP Protection With 4 New Patents
Via Benzinga
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Via Benzinga
PsyBio Therapeutics Reports Interim Third Quarter 2022 Financial Results
Via Benzinga
Yeast Produces Bread And Psilocybin, This Company Is Moving Into Clinical Trial Phase
Via Benzinga
Most, But Not All, Psychedelics Companies Have Sufficient Liquidity
Via Benzinga
DMT Producer PsyBio And Shrooms Grower Red Light Holland Share Their Most Recent Financial Results
Via Benzinga
PsyBio Therapeutics Presents "How Genetically Modified Bacteria Can Yield Best-In-Class Psychedelics" At The Psychedelic Capital Conference
Via Benzinga
Cannabis Movers & Shakers: Burns & Levinson, Water Ways, Chill Brands, Rubicon Organics
Via Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Via Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Via Benzinga
Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study
Via Benzinga
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Via Benzinga
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.